Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Scheinberg

Showing results (351-360 of 426) with videos related to

Pageof 43
Sort By:
Cancer Research|March 31, 2001
Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591)A M Ballangrud, W H Yang, D E Charlton, et al.
JCI Insight|November 16, 2018
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutationsPatrizia Mondello, Elliott J Brea, Elisa De Stanchina, et al.
Cancer Immunology, Immunotherapy : CII|June 10, 2010
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancerLee M Krug, Tao Dao, Andrew B Brown, et al.
JCI Insight|March 30, 2017
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutationsPatrizia Mondello, Elliott J Brea, Elisa De Stanchina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2006
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemiaNicole Lamanna, Matt Kalaycio, Peter Maslak, et al.
Blood Advances|May 13, 2022
Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatmentChristopher M Bourne, Sung Soo Mun, Tao Dao, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 24, 1999
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemiaG Sgouros, A M Ballangrud, J G Jurcic, et al.
Blood|January 25, 2023
Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blockerMegan M Dacek, Keifer G Kurtz, Patrick Wallisch, et al.
Plos One|September 20, 2007
PET imaging of soluble yttrium-86-labeled carbon nanotubes in miceMichael R McDevitt, Debjit Chattopadhyay, Jaspreet S Jaggi, et al.
Journal for Immunotherapy of Cancer|January 14, 2026
Trispecific targeting of T cells engineered with TCR mimic antibodies to limit antigen escapeTao Dao, Guangyan Xiong, Jeremy Meyerberg, et al.
Pageof 43

Showing results (351-360 of 426) with videos related to

Sort By:
Pageof 43
Cancer Research|March 31, 2001
Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591)A M Ballangrud, W H Yang, D E Charlton, et al.
JCI Insight|November 16, 2018
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutationsPatrizia Mondello, Elliott J Brea, Elisa De Stanchina, et al.
Cancer Immunology, Immunotherapy : CII|June 10, 2010
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancerLee M Krug, Tao Dao, Andrew B Brown, et al.
JCI Insight|March 30, 2017
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutationsPatrizia Mondello, Elliott J Brea, Elisa De Stanchina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2006
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemiaNicole Lamanna, Matt Kalaycio, Peter Maslak, et al.
Blood Advances|May 13, 2022
Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatmentChristopher M Bourne, Sung Soo Mun, Tao Dao, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 24, 1999
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemiaG Sgouros, A M Ballangrud, J G Jurcic, et al.
Blood|January 25, 2023
Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blockerMegan M Dacek, Keifer G Kurtz, Patrick Wallisch, et al.
Plos One|September 20, 2007
PET imaging of soluble yttrium-86-labeled carbon nanotubes in miceMichael R McDevitt, Debjit Chattopadhyay, Jaspreet S Jaggi, et al.
Journal for Immunotherapy of Cancer|January 14, 2026
Trispecific targeting of T cells engineered with TCR mimic antibodies to limit antigen escapeTao Dao, Guangyan Xiong, Jeremy Meyerberg, et al.
Pageof 43